Cross-Talk between Estrogen Receptor and Growth Factor Pathways As A Molecular Target for Overcoming Endocrine Resistance

Clinical Cancer Research

Volumn 10, Issue 1 II, 2004, Pages

  Schiff, Rachel ^a   Massarweh, Suleiman A ^a   Shou, Jiang ^a   Bharwani, Lavina ^a   Mohsin, Syed K ^a   Osborne, C Kent ^a   Nicholson, Robert ^b   Ellis, Matthew ^b   Santen, Richard ^b   Brown, Myles ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MS: 600 ^*

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GEFITINIB; GROWTH FACTOR; LAPATINIB; PROTEIN TYROSINE KINASE INHIBITOR; TAMOXIFEN; TRASTUZUMAB;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER INHIBITION; CLINICAL TRIAL; CONFERENCE PAPER; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG TARGETING; GENE ACTIVITY; GENE CONTROL; GENE EXPRESSION; HUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; RECEPTOR INTRINSIC ACTIVITY; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; GROWTH SUBSTANCES; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS, HORMONE-DEPENDENT; PROTEIN BINDING; RECEPTOR CROSS-TALK; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION;

EID: 9144256614     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-031212     Document Type: Conference Paper

References (52)

1. Osborne, C. K. Tamoxifen in the treatment of breast cancer. N. Engl. J. Med., 339: 1609-1618, 1998.
2. Nicholson, R. I., McClelland, R. A., Robertson, J. F., and Gee, J. M. Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. Endocr. Relat. Cancer, 6: 373-387, 1999.
3. Ali, S., and Coombes, R. C. Endocrine-responsive breast cancer and strategies for combating resistance. Nat. Rev. Cancer, 2: 101-112, 2002.
4. Schiff, R., Massarweh, S., Shou, J., and Osborne, C. K. Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. Clin. Cancer Res., 9: 447S-454S, 2003.
5. Newman, S. P., Bates, N. P., Vernimmen, D., Parker, M. G., and Hurst, H. C. Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer. Oncogene, 19: 490-497, 2000.
6. Yarden, R. I., Wilson, M. A., and Chrysogelos, S. A. Estrogen suppression of EGFR expression in breast cancer cells: A possible mechanism to modulate growth. J. Cell Biochem., 81: 232-246, 2001.
7. Salvatori, L., Pallante, P., Ravenna, L., Chinzari, P., Frati, L., Russo, M. A., and Petrangeli, E. Oestrogens and selective oestrogen receptor (ER) modulators regulate EGF receptor gene expression through human ER α and β subtypes via an Sp1 site. Oncogene. 22: 4875-4881, 2003.
8. Witton, C. J., Reeves, J. R., Going, J. J., Cooke, T. G., and Bartlett, J. M. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J. Pathol., 200: 290-297, 2003.
9. Konecny, G., Pauletti, G., Pegram, M., Untch, M., Dandekar, S., Aguilar, Z., Wilson, C., Rong, H. M., Bauerfeind, I., Felber, M., Wang, H. J., Beryt, M., Seshadri, R., Hepp, H., and Slamon, D. J. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J. Natl. Cancer Inst., 95: 142-153, 2003.
10. Schiff, R., and Fuqua, S. A. W. The importance of the estrogen receptor in breast cancer. In: Pasqualini, JR (ed.), Breast Cancer: Prognosis, Treatment, and Prevention, pp. 149-186. New York, Basel: Marcel Dekker, Inc., 2002.
11. McKenna, N. J., Lanz, R. B., and O'Malley, B. W. Nuclear receptor coregulators: cellular and molecular biology. Endocr. Rev., 20: 21-344, 1999.
12. Weigel, N. L., and Zhang, Y. Ligand-independent activation of steroid hormone receptors. J. Mol. Med., 76: 469-479, 1998.
13. Campbell, R. A., Bhat-Nakshatri, P., Patel, N. M., Constantinidou, D., Ali, S., and Nakshatri, H. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor α: a new model for anti-estrogen resistance. J. Biol. Chem., 276: 9817-9824, 2001.
14. Font de Mora, J., and Brown, M. AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol. Cell Biol., 20: 5041-5047, 2000.
15. Losel, R. M., Falkenstein, E., Feuring, M., Schultz, A., Tillmann, H. C., Rossol-Haseroth, K., and Wehling, M. Nongenomic steroid action: controversies, questions, and answers. Physiol. Rev., 83: 965-1016, 2003.
16. Cato, A. C., Nestl, A., and Mink, S. Rapid actions of steroid receptors in cellular signaling pathways. Sci. STKE, 2002: RE9, 2002.
17. Ho, K. J., and Liao, J. K. Nonnuclear actions of estrogen. Arterioscler. Thromb. Vasc. Biol., 22: 1952-1961, 2002.
18. Kousteni, S., Chen, J. R., Bellido, T., Han, L., Ali, A. A., O'Brien, C. A., Plotkin, L., Fu, Q., Mancino, A. T., Wen, Y., Vertino, A. M., Powers, C. C., Stewart, S. A., Ebert, R., Parfitt, A. M., Weinstein, R. S., Jilka, R. L., and Manolagas, S. C. Reversal of bone loss in mice by nongenotropic signaling of sex,steroids. Science (Wash. DC), 298: 843-846, 2002.
19. Li, L., Haynes, M. P., and Bender, J. R. Plasma membrane localization and function of the estrogen receptor α variant (ER46) in human endothelial cells. Proc. Natl. Acad. Sci. USA, 100: 4807-4812, 2003.
20. Figtree, G. A., McDonald, D., Watkins, H., and Channon, K. M. Truncated estrogen receptor α 46-kDa isoform in human endothelial cells: relationship to acute activation of nitric oxide synthase. Circulation, 107: 120-126, 2003.
21. Anderson, R. G. The caveolae membrane system. Annu. Rev. Biochem., 67: 199-225, 1998.
22. Filardo, E. J. Epidermal growth factor receptor (EGFR) transactivation by estrogen via the G-protein-coupled receptor, GPR30: a novel signaling pathway with potential significance for breast cancer. J. Steroid Biochem. Mol. Biol., 80: 231-238, 2002.
23. Flouriot, G., Brand, H., Denger, S., Metivier, R., Kos, M., Reid, G., Sonntag-Buck, V., and Gannon, F. Identification of a new isoform of the human estrogen receptor-α (hER-α) that is encoded by distinct transcripts and that is able to repress hER-α activation function 1. EMBO J., 19: 4688-4700, 2000.
24. Levin, E. R. Cellular functions of plasma membrane estrogen receptors. Steroids, 67: 471-475, 2002.
25. Levin, E. R. Cell localization, physiology, and nongenomic actions of estrogen receptors. J. Appl. Physiol., 91: 1860-1867, 2001.
26. Kahlert, S., Nuedling, S., van Eickels, M., Vetter, H., Meyer, R., and Grohe, C. Estrogen receptor α rapidly activates the IGF-1 receptor pathway. J. Biol. Chem., 275: 18447-18453, 2000.
27. Chung, Y. L., Sheu, M. L., Yang, S. C., Lin, C. H., and Yen, S. H. Resistance to tamoxifen-induced apoptosis is associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast cancer. Int. J. Cancer, 97: 306-312, 2002.
28. Razandi, M., Pedram, A., Park, S. T., and Levin, E. R. Proximal events in signaling by plasma membrane estrogen receptors. J. Biol. Chem., 278: 2701-2712, 2003.
29. Migliaccio, A., Castoria, G., Di Domenico, M., de Falco, A., Bilancio, A., Lombardi, M., Bottero, D., Varricchio, L., Nanayakkara, M., Rotondi, A., and Auricchio, F. Sex steroid hormones act as growth factors. J. Steroid Biochem. Mol. Biol., 83: 31-35, 2002.
30. Wong, C. W., McNally, C., Nickbarg, E., Komm, B. S., and Cheskis, B. J. Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade. Proc. Natl Acad. Sci. USA, 99: 14783-14788, 2002.
31. Song, R. X., McPherson, R. A., Adam, L., Bao, Y., Shupnik, M., Kumar, R., and Santen, R. J. Linkage of rapid estrogen action to MAPK activation by ERα-Shc association and Shc pathway activation. Mol. Endocrinol., 16: 116-127, 2002.
32. Sun, M., Paciga, J. E., Feldman, R. I., Yuan, Z., Coppola, D., Lu, Y. Y., Shelley, S. A., Nicosia, S. V., and Cheng, J. Q. Phosphatidylinositol-3-OH kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor α (ERα) via interaction between ERα and PI3K. Cancer Res., 61: 5985-5991, 2001.
33. Stoica, G. E., Franke, T. F., Wellstein, A., Morgan, E., Czubayko, F., List, H. J., Reiter, R., Martin, M. B., and Stoica, A. Heregulin-β1 regulates the estrogen receptor-α gene expression and activity via the ErbB2/PI 3-K/Akt pathway. Oncogene, 22: 2073-2087, 2003.
34. Shou, J., Massarweh, S., Ge, M., Mohsin, S. K., Ali, S., Wakeling, A. E., Ali, S., Osborne, C. K., and Schiff, R. Blockade of the estrogen receptor/growth factor cross-talk implicated in breast cancer tamoxifen resistance using a selective EGFR TK inhibitor. Proc. Am. Assoc. Cancer Res., 43: 1001, 2002.
35. Figtree, G. A., Webb, C. M., and Collins, P. Tamoxifen acutely relaxes coronary arteries by an endothelium-, nitric oxide-, and estrogen receptor-dependent mechanism. J. Pharmacol. Exp. Ther., 295: 519-523, 2000.
36. Kumar, R., Wang, R. A., Mazumdar, A., Talukder, A. H., Mandal, M., Yang, Z., Bagheri-Yarmand, R., Sahin, A., Hortobagyi, G., Adam, L., Barnes, C. J., and Vadlamudi, R. K. A naturally occurring MTA1 variant sequesters oestrogen receptor-α in the cytoplasm. Nature (Lond.), 418: 654-657, 2002.
37. Dowsett, M. Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer. Endocr. Relat. Cancer, 8: 191-195, 2001.
38. Massarweh, S., Shou, J., Mohsin, S. K., Ge, M., Wakeling, A. E., Osborne, C. K., and Schiff, R. Inhibition of epidermal growth factor/HER2 receptor signaling using ZD1839 ('Iressa') restores tamoxifen sensitivity and delays resistance to estrogen deprivation in HER2-overexpressing breast tumors Proc. Am. Soc. Clin. Oncol. (ASCO). Annu. Meet., 21: 33a, 2002.
39. Kurokawa, H., Lenferink, A. E., Simpson, J. F., Pisacane, P. I., Sliwkowski, M. X., Forbes, J. T., and Arteaga, C. L. Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res., 60: 5887-5894, 2000.
40. Santen, R. J., Song, R. X., McPherson, R., Kumar, R., Adam, L., Jeng, M. H., and Yue, W. The role of mitogen-activated protein (MAP) kinase in breast cancer. J. Steroid Biochem. Mol. Biol., 80: 239-256, 2002.
41. Osborne, C. K., Bardou, V., Hopp, T. A., Chamness, G. C., Hilsenbeck, S. G., Fuqua, S. W. A., Wong, J., Allred, C. D., Clark, G. M., and Schiff, R. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J. Natl. Cancer Inst., 95: 35361, 2003.
42. Ellis, M. J., Coop, A., Singh, B., Mauriac, L., Llombert-Cussac, A., Janicke, F., Miller, W. R., Evans, D. B., Dugan, M., Brady, C., Quebe-Fehling, E., Borgs, and M. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J. Clin. Oncol., 19: 3808-3816, 2001.
43. Dancey, J. E., and Freidlin, B. Targeting epidermal growth factor receptor-are we missing the mark? Lancet, 362: 62-64, 2003.
44. McKeage, K., and Perry, C. M. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs, 62: 209-243, 2002.
45. Massarweh, S., Shou, J., DiPietro, M., Mohsin, S. K., Hilsenbeck, S. G., Wakeling, A. E., Osborne, C. K., and Schiff, R. Targeting the epidermal growth factor receptor pathway improves the anti-tumor effect of tamoxifen and delays acquired resistance in a xenograft model of breast cancer. 25th Annual San Antonio Breast Cancer Symposium, San Antonio, Breast Cancer Res. Treat., 76: S33, 2002.
46. Nicholson, R. I., Hutcheson, I. R., Harper, M. E., Knowlden, J. M., Barrow, D., McClelland, R. A., Jones, H. E., Wakeling, A. E., and Gee, J. M. Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen-receptor-positive breast cancer. Ann. NY Acad. Sci., 963: 104-115, 2002.
47. Witters, L., Engle, L., and Lipton, A. Restoration of estrogen responsiveness by blocking the HER-2/neu pathway. Oncol. Rep., 9: 1163-1166, 2002.
48. Blackwell, K., Spector, N., Snyder, S., Marks, J., Xia, W., Liu, L-H., Broadwater, G., McDonnell, D., and Dewhirst, M. GW572016, a novel dual EGFR/Her-2 small molecule, tyrosine kinase inhibitor induces regression and significant growth delay in tamoxifen-resistant, MCF-7 derived tumors. 25th Annual San Antonio Breast Cancer Symposium, San Antonio, Breast Cancer Res. Treat., 76: S13, 2002.
49. Robertson, J. F. R., Gutteridge, E., Cheung, K. L., Owers, R., Koehler, M., Hamilton, L., Gee, J., and Nicholson, R. I. Gefitinib (ZD1839) is active in acquired tamoxifen (TAM)-resistant oestrogen receptor (ER)-positive and ER-negative breast cancer: Results from a phase II study. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 22: 7, 2003.
50. Albain, K., Elledge, R., Gradishar, W. J., Hayes, D. F., Rowinsky, E., Hudis, C., Pusztai, L., Tripathy, D., Modi, S., and Rubin, S. Open-label, Phase II, multicenter trial of ZD1839 ('Iressa') in patients with advanced breast cancer. 25th San Antonio Breast Cancer Symposium, San Antonio, Breast Cancer Res. Treat., 76: S33, 2002.
51. Baselga, J., Albanell, J., Ruiz, A., Lluch, A., Gascon, P., Gonzalez, S., Guillen, V., Sauleda, S., Averbuch, S., and Rojo, F. Phase II and tumor pharmacodynamic study of gefinitib (ZD1839) in patients with advanced breast cancer. Proc. Am. Soc. Clin. Oncol. (ASCO). Annu. Meet., 7, 2003.
52. Bardou, V. J., Arpino, G., Elledge, R. M., Osborne, C. K., and Clark, G. M. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J. Clin. Oncol., 21: 1973-1979, 2003.